Rituximab, mycophenolate mofetil compared for pemphigus vulgaris
Rogue antibodies wreak havoc in severe COVID-19 cases
19 May 2021Novel approach identifies genes linked to autism and predicts patient IQ
19 May 2021Rituximab, mycophenolate mofetil compared for pemphigus vulgaris
(HealthDay)—For patients with pemphigus vulgaris, rituximab is superior to mycophenolate mofetil for producing sustained complete remission at 52 weeks, according to a study published online May 19 in the New England Journal of Medicine to coincide with the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research, held virtually from May 17 to 20.
